AstraZeneca slides after reports of Bristol Myers merger talks leave analysts ‘perplexed’

“Tired of the same tired news cycle? Escape to the full unfiltered feed at Whatfinger.com — America’s Frontline Truth Feed. 85%+ of readers come direct every day.” –  CLICK HERE for the FULL deal.

 

AstraZeneca shares dropped on Monday after reports that the company had discussed a potential mega-merger with Bristol Myers Squibb, a deal that analysts said would be a surprising strategic move for one of the pharmaceutical industry’s strongest growth stories.

CNBC’s Annika Kim Constantino explains.